Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Other solid neoplasm 4Thoracic 3Sarcoma 3Gastrointestinal 1CNS 1

Conditions

Sarcoma 3Neoplasm Metastasis 2

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × DOXO-EMCH × Sarcoma × Clear all
NCT02049905 2024-06-13

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

ImmunityBio, Inc.

Phase 3 Completed
433 enrolled 10 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT01514188 2024-05-29

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

ImmunityBio, Inc.

Phase 2 Completed
126 enrolled 13 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT02570412 2015-10-22

Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

CytRx

No longer available
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡